SEO URLwww.firestrike.ai/deals/vir-astellas-pharma-acquisition-2026
acquisitionAnnounced · Feb 24, 2026BiotechnologySource · CredibleArticle · Factual
Astellas Pharma acquires VIR
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$1.71B
Target
VIR
NASDAQ:VIR · San Francisco, California
Acquirer
Astellas Pharma
Collaboration
Status
Announced
Astellas Pharma agreed to acquire VIR. Reported deal value: $1.71B. Status: Announced. Sector: Biotechnology. Target headquarters context: San Francisco, California, United States.
This page summarizes publicly available information about the transaction as of 2026-02-24. Figures and status may change as filings and press coverage update.
ALLISON GATLIN Updated 04 :09 PM ET 02/24/2026 Vir stock catapulted early Tuesday after the small biotech company smashed Wall Street fourth-quarter sales expectations and signed a collaboration deal with Astellas Pharma
Deal timeline
Announced
Feb 24, 2026 · investors.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biotechnology with a reported deal value of $1.71B. Figures and status may change as sources update.
Sources: investors.com · Primary article · FireStrike proprietary index